Empirical micafungin treatment and survival without invasive fungal infection in adults with icu-acquired sepsis, candida colonization, and multiple organ failure the empiricus randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 316, Issue 15, 2016, Pages 1555-1564

  Timsit, Jean Francois ^a   Azoulay, Elie ^a   Schwebel, Carole ^a   Charles, Pierre Emmanuel ^a   Cornet, Muriel ^a   Souweine, Bertrand ^a   Klouche, Kada ^a   Jaber, Samir ^a   Trouillet, Jean Louis ^a   Bruneel, Fabrice ^a   Argaud, Laurent ^a   Cousson, Joel ^a   Meziani, Ferhat ^a   Gruson, Didier ^a   Paris, Adeline ^a   Darmon, Michael ^a   Garrouste Orgeas, Maité ^a   Navellou, Jean Christophe ^a   Foucrier, Arnaud ^a   Allaouchiche, Bernard ^a   Das, Vincent ^a   Gangneux, Jean Pierre ^a   Ruckly, Stéphane ^a   Maubon, Daniele ^a   Jullien, Vincent ^a   Wolff, Michel ^a   more..

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA 1,3 GLUCAN; MICAFUNGIN; PLACEBO; ANTIFUNGAL AGENT; ECHINOCANDIN; LIPOPEPTIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANDIDA; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; FEMALE; FRANCE; FUNGAL COLONIZATION; HAZARD RATIO; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC MYCOSIS; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA; CANDIDIASIS; CANDIDIASIS, INVASIVE; CLINICAL TRIAL; CRITICAL ILLNESS; CROSS INFECTION; DRUG ADMINISTRATION; MICROBIOLOGY; MIDDLE AGED; MORTALITY; TIME FACTOR;

AGED; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CANDIDIASIS; CANDIDIASIS, INVASIVE; CRITICAL ILLNESS; CROSS INFECTION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ECHINOCANDINS; FEMALE; HUMANS; LIPOPEPTIDES; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; TIME FACTORS;

EID: 84997418983     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.14655     Document Type: Article

References (33)

1. Lortholary O, Renaudat C, Sitbon K, et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med. 2014;40(9):1303-1312.
2. BassettiM, Righi E, Ansaldi F, et al. A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med. 2014;40(6):839-845.
3. Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012;54(12):1739-1746.
4. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med. 2013;57(4):857-863.
5. Schuster MG, Edwards JE Jr, Sobel JD, et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med. 2008;149(2):83-90.
6. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med. 2002;28(12):1708-1717.
7. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg. 2001;233(4):542-548.
8. Piarroux R, Grenouillet F, Balvay P, et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med. 2005;32(12):2443-2449.
9. Golan Y,Wolf MP, Pauker SG,Wong JB, Hadley S. Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. Ann Intern Med. 2005;143(12):857-869.
10. Ostrosky-Zeichner L, Shoham S, Vazquez J, et al. MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis. 2014;58(9):1219-1226.
11. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50.
12. Azoulay E, Dupont H, Tabah A, et al. Systemic antifungal therapy in critically ill patients without invasive fungal infection. Crit Care Med. 2012;40 (3):813-822.
13. Bailly S, Bouadma L, Azoulay E, et al. Failure of empirical systemic antifungal therapy in mechanically ventilated critically ill patients. Am J Respir Crit Care Med. 2015;191(10):1139-1146.
14. Eggimann P, Pittet D. Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later. Intensive Care Med. 2014;40(10):1429-1448.
15. Le C, Ostrosky-Zeichner L, Schuster P. What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients. Intensive Care Med. 2014;40(6):808-819.
16. Timsit JF, Azoulay E, CornetM, et al. EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial. Trials. 2013;21 (14):399.
17. Tissot F, Lamoth F, Hauser PM, et al.-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit Care Med. 2013;188(9):1100-1109.
18. Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med. 2015;373(15):1445-1456.
19. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed. 1999;59(1):19-29.
20. Delattre IK, Musuamba FT, Nyberg J, et al. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients. Ther Drug Monit. 2010;32(6):749-756.
21. KnausWA, Zimmerman JE,Wagner DP, Draper EA, Lawrence DE. Crit Care Med. 1981;9(8):591-597.
22. Azoulay E, Cohen Y, Zahar JR, et al. Practices in non-neutropenic ICU patients with Candida-positive airway specimens. Intensive Care Med. 2004;30(7):1384-1389.
23. Troughton JA, Browne G, McAuley DF,Walker MJ, Patterson CC, McMullan R. Prior colonisation with Candida species fails to guide empirical therapy for candidaemia in critically ill adults. J Infect. 2010;61(5):403-409.
24. Barenfanger J, Arakere P, Cruz RD, et al. Improved outcomes associated with limiting identification of Candida spp. in respiratory secretions. J Clin Microbiol. 2003;41(12):5645-5649.
25. Bailly S, Maubon D, Fournier P, et al. Impact of antifungal prescription on relative distribution and susceptibility of Candida spp.-trends over 10 years. J Infect. 2016;72(1):103-111.
26. DannaouiE,Desnos-OllivierM,Garcia-HermosoD, et al; FrenchMycoses Study Group.Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg Infect Dis. 2012;18(1):86-90.
27. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F; French Mycosis Study Group. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 2011;55(2):532-538.
28. Bailly S, Leroy O, Montravers P, et al. Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data. Intensive Care Med. 2015;41(11):1931-1940.
29. Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L. (1,3)-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis. 2012;55(4):521-526.
30. Lempers VJ, Schouten JA, Hunfeld NG, et al. Altered micafungin pharmacokinetics in intensive care unit patients. Antimicrob Agents Chemother. 2015;59(8):4403-4409.
31. Leon C, Ruiz-Santana S, Saavedra P, et al. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med. 2009;37(5):1624-1633.
32. Leroy O, Gangneux JP, Montravers P, et al; AmarCand Study Group. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med. 2009;37(5):1612-1618.
33. Ostrosky-Zeichner L. Clinical prediction rules for invasive candidiasis in the ICU: ready for prime time Crit Care. 2011;15(5):189.